OZURDEX 700 micrograms intravitreal implant in applicator

DRUG3 trials

Sponsors

Oxular IE Limited, Centre Hospitalier Universitaire De Dijon, Hospices Civils De Lyon

Conditions

Diabetic Macular Edema (DME)Diabetic Macular OedemaDiabetic macular oedema

Phase 2

A Multi-Center, Randomized, Parallel-Group, Phase 2, Masked, Three-Arm Trial to Compare Safety, Tolerability, Efficacy, and Durability of Two Dose Levels of Suprachoroidal Sustained-Release OXU-001 (Dexamethasone Microspheres; DEXAspheres®) Using the Oxulumis® Illuminated Microcatheterization Device Compared with Intravitreal Dexamethasone Implant (OZURDEX®) in Subjects with Diabetic Macular Edema (OXEYE).

CompletedCTIS2023-503496-17-00

Oxular IE LimitedDiabetic Macular Edema (DME)

End: 2023-12-11Target: 44Updated: 2023-08-21

LOADEX: PILOT AND PHASE 2 STUDY OF THE EFFICACY OF A TREATMENT PROTOCOL WITH DEXAMETHASONE IMPLANT LOADING DOSE IN PATIENTS WITH DIABETIC MACULAR EDEMA

RecruitingCTIS2024-514362-39-00

Hospices Civils De LyonDiabetic macular oedema

Start: 2019-12-05Target: 100Updated: 2026-01-12

Phase 4

EMMA - Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema

RecruitingCTIS2024-513983-24-00

Centre Hospitalier Universitaire De DijonDiabetic Macular Oedema

Start: 2021-10-29Target: 106Updated: 2025-04-30